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VitaminD deficiency appears to be an underestimated risk factor for cardiovascular disease in patients with chronic kidney disease.
Evidence from both basic science and clinical studies supports the possible protective role of vitamin D beyond its eﬀect onmineral
metabolism. Toxicity of pharmacologic doses of active vitaminDmetabolites, in particular calcitriol, ismainly due to the possibility
of positive calcium and phosphorus balance. Therefore, vitamin D analogs have been developed, which suppress PTH secretion
and synthesis with reduced calcemic and phosphatemic eﬀects. Observational studies suggest that in hemodialysis patients the use
of a vitamin D receptor (VDR) activator, such as calcitriol, doxercalciferol, paricalcitol, or alfacalcidol, is associated with a reduced
mortality when compared with nonusers of any VDR activator. In this article the existing literature on the topic is reviewed,
although a more robust answer to the question of whether or not VDR activators have beneficial eﬀects in hemodialysis patients
will hopefully come from a randomized controlled trial.
1. Introduction
Chronic kidney disease (CKD) is associated with increased
cardiovascular events and mortality when the glomerular
filtration rate declines below 60mL/min [1–3]. One signifi-
cant event in CKD patients is the development of calcitriol
deficiency secondary to the reduction/absence of kidney
α1-hydroxylase which mediates the final hydroxylation step
of 25(OH)vitamin-D to 1,25-(OH)2vitamin-D, or calcitriol
[4, 5]. 1,25-(OH)2vitamin-D deficiency causes parathyroid
hyperplasia and increased parathyroid hormone [6]; the
consequent hyperparathyroidism and hyperphosphatemia
are important risk factors for mortality in CKD patients
[4, 7]. Accordingly, vitamin D treatment is associated with a
reduced rate of cardiovascular diseases and mortality [5, 8].
Several studies also underline the side eﬀects of calcitriol
treatment, such as hypercalcemia and hyperphosphatemia,
which carry an increased risk of cardiovascular calcifications.
Compared to calcitriol, vitamin D analogs, such as pari-
calcitol, cause less hypercalcemia and hyperphosphatemia
because of less bone resorption and less intestinal absorption
[9, 10]. Calcitriol and vitamin D analogs are better identified
as Vitamin D receptor activators.
In addition to suppression of PTH, use of vitamin D
receptor activators has been associated with other eﬀects:
reduced hospitalization and mortality, prevention of cardio-
vascular diseases, vascular calcification and atherosclerosis,
inhibition of the rennin-angiotensin system, preservation
form cellular senescence, improved endothelial function,
reduced tubular interstitial fibrosis, and reduced inflamma-
tory status.
Studies about vitamin D receptor activators and clinical
outcomes (Table 1) in chronic kidney disease are reviewed in
this article.
2. Materials and Methods
We researched on PubMed (US National Center for Biotech-
nology Information) all the articles about “paricalcitol and
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Table 1: Vitamin D receptor activators: summary of clinical
outcomes.
Suppression of PTH
Incidence of hypercalcemia and hyperphosphatemia
Mineral metabolism and bone disorder
Hospitalization
Mortality
Cardiovascular protection
Prevention of Atheroscleroisis
Renal protection and reduction proteinuria
Renal protection and renin-angiotensin system
Renal protection and tubular interstitial fibrosis
Anti-inflammatory eﬀect
Cellular senescence
Endothelial function
outcomes,” “doxercalciferol and outcomes,” and “maxacalci-
tol and outcomes” and we found 41 articles: 29 studies on
paricalcitol (8 randomized controlled trial, 3 observational
studies, 1 open label study, 5 retrospective studies, 1 review,
and 10 experimental studies in animals), 4 studies on doxer-
calciferol (3 randomized controlled studies, 1 observational
study), 7 studies on maxacalcitol (6 observational studies
and 1 experimental study on mice), and 1 experimental
study comparing two vitamin D analogs, paricalcitol and
doxecalciferol.
3. Results and Discussion
3.1. Suppression of PTH: Eﬀects on Calcium
and Phosphate Levels
3.1.1. Comparing Paricalcitol and Placebo (Table 2). Coyne et
al. [11] found that 91% of patients treated with paricalcitol
reached two consecutive PTH level reductions of 30%
or greater versus 13% of placebo patients (P < .001),
while incidences of hypercalcemia, hyperphosphatemia were
not significantly diﬀerent between two groups. Martin et
al. [12] demonstrated that 68% of patients treated with
paricalcitol had a 30% decrease in serum PTH for 4
consecutive weeks—without evidence of hypercalcemia and
hyperphosphatemia—versus 8% of patients treated with
placebo (P < .001) (12). Lindberg et al. [13] showed,
in an open-label study, that PTH levels fell into target
range by month 5 without episodes of hypercalcemia and
hyperphosphatemia.
3.1.2. Comparing Paricalcitol and Calcitriol (Table 2). A
multicenter, double-blind RCT conducted by Sprague et al.
[14] demonstrated that paricalcitol patients have ≥50% and
faster reduction in baseline PTH versus calcitriol patients;
they also showed that hypercalcemic episodes were 18%
for paricalcitol versus 33% for calcitriol (P < .01). In a
retrospective study, Mittman et al. [15] found that PTH
levels were significantly lower for paricalcitol versus calcitriol
(247 versus 190 pg/mL) while episodes of hypercalcemia and
hyperphosphatemia were significantly fewer for paricalcitol
versus calcitriol. A crossover study conducted by Coyne et
al. [16] demonstrated that suppression of PTH at 36 hours
was significantly greater after administration of 160 μg of
paricalcitol (63.6% ± 2.3%) versus calcitriol (but similar
after administration of 160 μg of paricalcitol), while the
increase of serum calcium is greater in calcitriol group.
Lund et al. [17] in a single-center, double-blind, active-
controlled, randomized, crossover trial observed that frac-
tional intestinal calcium absorption was significantly lower
after paricalcitol versus calcitriol. Finally, Mittman et al.
[18] in a 2-year, single-center crossover study demonstrated
that conversion from calcitriol to paricalcitol resulted in
lower serum calcium (P < .001), lower serum phosphorus
(P < .05), reduced PTH (P = .001) and serum alkaline
phosphatase (P < .001).
3.1.3. Studies on other VDR Activators, Doxercalciferol, and
Maxacalcitol (Tables 3 and 4). In a crossover study compar-
ing paricalcitol and doxercalciferol, Joist et al. [19] observed
a similar suppression of PTH, while serum phosphorus
was significantly higher using doxercalciferol. In a double-
blind randomized study, Fraza˜o et al. [20], in an open-
label doxercalciferol treatment (16 weeks), and randomized,
double-blinded treatment with doxercalciferol or placebo (8
weeks), found that 80% of doxercalciferol patients showed a
70% reduction in PTH levels from baseline, although serum
calcium and phosphate levels increased respectively from
9.2 to 9.7mg/dL and from 5.4 to 5.9mg/dL. Coburn et al.
[21] in a randomized, double-blinded, placebo-controlled,
multicenter trial in 55 patients with stage 3 or 4 CKD showed
that iPTH levels decreased more in doxercalciferol treatment
versus placebo (P < .001); no significant diﬀerences in
mean serum calcium or phosphorus were observed between
the two groups. In a randomized study, Zisman et al. [22]
demonstrated that in patients on a maintenance dose of
paricalcitol, dosing doxercalciferol at 55–60% of the pari-
calcitol dose results in comparable inhibition of PTH, with
similar incidences of hypercalcemia and hyperphosphatemia.
Comparing maxacalcitol and calcitriol, Hayashi et al. [23]
found no significant diﬀerences between the two groups in
serum iPTH and phosphorus concentration, while serum
calcium was significantly higher in the maxacalcitol versus
calcitriol group during early treatment, but not at the end
of treatment. Shiizaki et al. [24], in a study conducted in
5/6 nephrectomized rats treated by a direct injection of
maxacalcitol into the parathyroid gland, found a significant
decrease of PTH versus rats treated by vehicle, along with
upregulation of both VDR and CaSR in the parathyroid
tissue; no diﬀerences in calcium and phosphorus levels were
observed between two groups. Kazama et al. [25] found
that both maxacalcitol and calcitriol significantly decreased
plasma intact PTH levels and increased serum Ca levels, but
PTH levels were significantly lower in the maxacalcitol group
after 24 weeks of treatment. In addition, serum phosphate
levels were significantly higher in the calcitriol group. Thus,
these authors proposed maxacalcitol as a possible less phos-
phatemic active vitamin D agent which might reduce the risk
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Table 2: Suppression of PTH and eﬀects on calcium and phosphate levels: paricalcitol versus placebo and paricalcitol versus calcitriol.
Author Year Study Outcome 1 Outcome 2
Coyne et al. [11] 2006
Three randomized,
placebo-controlled, phase-3 trials
were conducted in 220 patients
with stage 3 and 4 CKD with
secondary hyperparathyroidism.
24-week studies
Decreases in PTH levels of 30%
or greater in 91% of paricalcitol
versus 13% of placebo patients
(P < .001)
Incidences of hypercalcemia,
hyperphosphatemia, and
elevated Ca × P were not
significantly diﬀerent between
groups
Martin et al. [12] 1998
3 double-blind RCTs
n = 78 dialysis patients 12-week
study
27 of 40 patients receiving
paricalcitol (68%) had a 30%
decrease in serum PTH for 4
consecutive weeks, versus 3 of 38
patients (8%) receiving placebo
(P < .001)
No evidence of hypercalcemia
and hyperphosphatemia
Lindberg et al. [13] 2001
Open-label study
n = 164 dialysis patients.
13-month study
Mean PTH levels fell into target
range (100–300pg/mL) by
month 5
Serum calcium and phosphorus
were in normal range
Sprague et al. [14] 2003
Multicenter, double-blind RCT;
n = 263 dialysis patients.
32-week study
Paricalcitol patients had a ≥50%
and faster reduction in baseline
PTH versus calcitriol patients (87
versus 107 days). Paricalcitol
patients reached a therapeutic
PTH range in 18 weeks versus
calcitriol patients who never
reached the target range
Hypercalcemic episodes were
18% for paricalcitol versus 33%
for calcitriol (P = .008)
Mittman et al. [15] 2004
Retrospective study
n = 101 dialysis patients
24-month study
PTH levels were significantly
lower for paricalcitol versus
calcitriol (247 versus 190 pg/mL)
Number of hypercalcemic
episodes were 111 for paricalcitol
versus 69 for calcitriol; number
of episodes of
hyperphosphatemia were 225 for
paricalcitol versus 186 for
calcitriol
Coyne et al. [16] 2002
Crossover study
n = 10 dialysis patients 36-hour
study
Suppression of PTH at 36 hours
was significantly greater after
administration of 160 μg of
paricalcitol (63.6% ± 2.3%)
versus calcitriol
Ca × P product increased more
after calcitriol administration
than after a 6- or 8-fold greater
dose of paricalcitol
Lund et al. [17] 2010
Single-center, double-blind,
active-controlled, randomized,
crossover trial. n = 22
hemodialysis patients
Fractional intestinal calcium
absorption was significantly
lower after paricalcitol (0.135 ±
0.006) versus calcitriol (0.158±
0.006, P = .022)
Mittman et al. [18] 2010
2-year, single-center crossover
study
n = 73 hemodialysis patients
converted from calcitriol to
paricalcitol using a 1 : 3
conversion ratio
Conversion from calcitriol to
paricalcitol resulted in lower
serum calcium (P < .001), lower
serum phosphorus (P < .05),
reduced PTH (P = .001) and
reduced serum alkaline
phosphatase (P < .001)
of extraskeletal calcification [25]. Oyama et al. [26] treated
patients with maxacalcitol intravenously and found that
lower pretreatment plasma iPTH and calcium levels, but not
phosphorus levels, were predictor of the response to treat-
ment with maxacalcitol. On the other hand, serum levels of
phosphorus did not significantly increase during treatment.
3.1.4. Parathyroid Hyperplasia (Table 5). Several studies
addressed the issue of parathyroid hyperplasia (Table 5).
Okuno et al. [27] demonstrated that the responsiveness to
maxacalcitol therapy of secondary hyperparathyroidism is
dependent on parathyroid gland size and that the simple
measurement of maximum parathyroid gland diameter by
ultrasonography may be useful for predicting responsiveness
to maxacalcitol treatment. They suggest that glands larger
than 11mmdo not adequately respond to treatment. Shiizaki
et al. [28] also studied 20 patients with SHPT and enlarged
parathyroid glands treated by percutaneous maxacalcitol
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Table 3: Suppression of PTH and eﬀects on calcium and phosphate levels: doxercalciferol versus
placebo and doxercalciferol versus paricalcitol.
Author Year Study Outcome 1 Outcome 2
Joist et al. [19] 2006
Crossover study
n = 13 dialysis patients 36-hour
study paricalcitol versus
doxercalciferol
Clinical suppression of PTH at
36 hours was comparable
between treatment arms (63%
following paricalcitol therapy
and 65% following
doxercalciferol therapy).
Serum phosphorus was
significantly higher during
administration of doxercalciferol
(2.12 ± 0.11mmol/L versus 1.85
± 0.07mmol/L).
Fraza˜o et al. [20] 2000
Double-blind, RCT
n = 99 dialysis patients 8-week
study
80% of doxercalciferol patients
showed a 70% reduction in PTH
levels from baseline, and 83% of
the doxercalciferol patients met
the study PTH targets.
During double-blinded
treatment, 3.26% and 0.46% of
[Ca] measurements exceeded
11.2mg/dl with doxercalciferol
and placebo, respectively.
Coburn et al. [21] 2004
RCT, n = 55 patients with stage 3
or 4 CKD treated with
doxercalciferol versus placebo.
Mean plasma iPTH level
decreased by 46% from baseline
after 24 weeks of doxercalciferol
treatment (P < .001), versus
placebo. After 6 weeks, iPTH
level decreased with
doxercalciferol versus placebo
(P < .001).
No significant diﬀerences in
mean serum calcium or
phosphorus between the groups.
Zisman et al. [22] 2005
RCT, n = 27 hemodialysis
patients randomized to receive
doxercalciferol at either 35, 50, or
65% of the paricalcitol dose for 6
weeks
A conversion factor of 0.57 for
the dose of doxercalciferol
relative to paricalcitol resulted in
equivalent suppression of iPTH
Incidences of hypercalcemia and
hyperphosphatemia were similar
for all groups
Table 4: Suppression of PTH and eﬀects on calcium and phosphate levels: maxacalcitol versus placebo and maxacalcitol versus calcitriol.
Author Year Study Outcome 1 Outcome 2
Hayashi et al.
[23]
2004
n = 91 patients
47 patients treated with calcitriol
versus 44 patients treated with
maxacalcitol for 12 months
There were no significant
diﬀerences between the two groups
in serum iPTH
No significant diﬀerences between
the two groups in phosphorus
concentration.
Serum calcium was significantly
higher in the maxacalcitol versus
calcitriol group during early
treatment, but not at the end of
treatment
Shiizaki et al.
[24]
2005
Uremic (5/6 NX) rats fed a
high-phosphate diet and treated by
a direct injection of
maxacalcitol-OCT (DI-OCT) or
vehicle (DI-vehicle)
DI-OCT decreased PTH levels with
a significant diﬀerence DI-OCT
versus DI-vehicle.
Upregulations of both VDR and
CaSR after DI-OCT were observed
versus DI-vehicle-treated rats.
Serum calcium and phosphorus
levels did not changed markedly in
both groups
Kazama et al.
[25]
2005
n = 126 nondiabetic hemodialysis
patients with PTH levels greater
than 300 pg/mL treated with either
maxacalcitol (n = 80) or calcitriol
(n = 46) for 24 weeks.
Both treatments decreased plasma
intact PTH levels (P < .0001) and
increased serum Ca levels
(P < .0001). PTH levels were
significantly lower in the
maxacalcitol group after 24 weeks
(P < .01).
Serum phosphate was significantly
greater in the calcitriol group
(P < .05)
Oyama et al.
[26]
2005
Nondiabetic dialysis patients
(n = 146) with iPTH levels
>300 pg/mL were treated with i.v.
maxacalcitol injected 3/week for 48
weeks.
96 patients were successfully treated
(iPTH levels < 300 pg/ml within 48
weeks). Pretreatment PTH and Ca
levels were lower in patients
successfully treated with
maxacalcitol.
Serum phosphorus levels did not
significantly increase.
Phosphorus levels were not
predictive of the response to
treatment with maxacalcitol.
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Table 5: Parathyroid hyperplasia.
Author Year Study Outcome
Okuno et al. [27] 2003
n = 25 patients treated with maxacalcitol (PTH
>300 pg/ml; mean maximal diameter of
parathyroid glands 11.0 ± 0.7mm before
treatment), divided in two groups:
group S gland diameter <11.0mm versus
group L with gland diameter >11.0mm.
Parathyroid volume was measured by
ultrasonography.
At 4–24 weeks after administration of
maxacalcitol, intact PTH concentrations
decreased significantly in group S (P < .01),
versus group L.
Serum calcium increased significantly in group
L (P < .05), versus group S.
Glands larger than 11mm do not adequately
respond to treatment.
Shiizaki et al. [28] 2003
n = 20 patients with SHPT and enlarged
parathyroid glands were treated by
percutaneous maxacalcitol injection therapy
(PMIT) under ultrasonographic guidance
consecutively 6 times, followed by i.v.
maxacalcitol.
PMIT and subsequent i.v. maxacalcitol
administration significantly decreased PTH
levels and parathyroid gland volume for at least
12 weeks.
Akizawa and Kurokawa [29] 2002
A trial on the long-term administration of
maxacalcitol (3 times weekly for 26 weeks
subsequent to a 26-week pretrial) in 124
dialysis patients with secondary
hyperparathyroidism.
PTH levels fell promptly and significantly and
were well controlled for one year. Serum
calcium levels rose significantly, but within a
physiological range. Hypercalcemia (33.1%)
was resolved or ameliorated after the
withdrawal or dose reduction of maxacalcitol.
Saito et al. [30] 2010
An outpatient treatment regimen using
percutaneous maxacalcitol injection therapy
(PMIT) on a weekly basis for 4–6 weeks
following dialysis.
Intact PTH decreased from 797 to 253 pg/mL.
Ultrasonographic examination detected a
gradual reduction in parathyroid gland volume
from 1.27 to 0.24 cm3.
Table 6: Mineral metabolism and bone disorder.
Author Year Study Outcome
Slatopolsky et al. [31] 2003
A study in uremic rats to assess
the eﬃcacy of paricalcitol in
prevention (protocol I) and
treatment (protocol II) of
hyperparathyroidism and renal
osteodystrophy.
Paricalcitol was eﬀective in
preventing (protocol I) and
suppressing (protocol II) the
significant hyperparathyroidism
induced by uremia and enhanced
by a high phosphorus diet; it
improved bone histology in
uremic rats aﬀected by severe
secondary hyperparathyroidism.
Kazama et al. [32] 2005
N = 50 chronic dialysis patients
with PTH levels >300 pg/mL
treated with 10 μg of i.v.
maxacalcitol thrice a week.
PTH, bone-specific alkaline
phosphatase and osteocalcin
levels were significantly lowered;
serum calcium levels increased.
Osteoprotegerin levels
significantly decreased
(P < .0001).
injection therapy, which significantly decreased the serum
intact-PTH level and parathyroid gland volume for at least
12 weeks. Akizawa and Kurokawa [29], in a trial on the long-
term administration of maxacalcitol, found that PTH levels
fell promptly and were well controlled for one year, with
doses ranging from 2.5 to 20mg per dialysis. Serum calcium
levels rose significantly, but within a physiological range;
episodes of hypercalcemia were present in 33% of patients.
Saito et al. [30] proposed an outpatient treatment regimen
using percutaneous maxacalcitol injection therapy on a
weekly basis for 4–6 weeks following dialysis. They found
no major complications and intact parathyroid hormone
decreased from 797 ± 178 pg/mL to 253 ± 25 pg/mL, while
the parathyroid gland volume gradually decreased from 1.27
± 1.06 cm3 to 0.24 ± 0.15 cm3.
3.2. Vitamin D Receptor Activators, Mineral Metabolism, and
Bone Disorders (Table 6). Activation of the vitamin D recep-
tor plays a role in bone metabolism and treatment with VDR
activators may favorably aﬀect bone disease. Slatopolsky et
al. [31] studied uremic rats to assess the eﬃcacy of parical-
citol in prevention and treatment of renal osteodystrophy.
Paricalcitol resulted eﬀective in preventing and suppressing
hyperparathyroidism induced by uremia and enhanced by
6 International Journal of Nephrology
Table 7: Hospitalization and mortality.
Author Year Study Outcome
Dobrez et al. [33] 2004
Data from January 1999 to November 2001;
n = 11443 hemodialysis patients who
received at least 10 doses of vitamin D
therapy
The paricalcitol group had a lower risk of first all-cause
hospitalization (14% less, P < .0001), fewer
hospitalizations per year (0.642 fewer, P < .001) and
fewer hospital days per year (6.84 fewer, P < .001)
versus calcitriol
Vervloet et al. [34] 2009
A review of observational studies that
examined the association between the use of
VDRA and mortality
Hospitalization is less frequent in patients treated with
paricalcitol versus patients treated with calcitriol
Teng et al. [35] 2003
A historical cohort study to compare the
36-month survival rate among dialysis
patients receiving treatment with
paricalcitol (29,021 patients) versus
calcitriol (38,378 patients).
The mortality rate among patients receiving paricalcitol
was 0.180 per person-year versus 0.223 per person-year
among those receiving calcitriol (P < .001). The
diﬀerence in survival was significant at 12 months and
increased with time. In the adjusted analysis, the
mortality rate was 16 percent lower (95% CI, 10 to 21
percent) among paricalcitol-treated patients than
among calcitriol-treated patients.
At 12 months, calcium and phosphorus levels had
increased by 6.7 and 11.9 percent, respectively, in the
paricalcitol group, as compared with 8.2 and 13.9
percent, respectively, in the calcitriol group (P < .001).
Tentori et al. [36] 2006
n = 7731 patients (calcitriol: n = 3212;
paricalcitol: n = 2087; doxercalciferol:
n = 2432) in the years 1999–2004. Median
follow-up was 37 weeks.
Mortality rates (deaths/100 patient-years) were
identical in patients treated with doxercalciferol (15.4,
95% CI 13.6–17.1) and paricalcitol (15.3, 13.6–16.9)
and higher in patients on calcitriol (19.6, 18.2–21.1)
(P < .0001). Overall, mortality was higher for patients
who did not receive vitamin D versus those who did.
a high phosphorus diet. In addition paricalcitol ameliorated
the histomorphometric changes induced by uremia and high
phosphorus diet, improving bone histology in uremic rats
aﬀected by severe secondary hyperparathyroidism. Kazama
et al. [32] treated 50 patients with hyperparathyroidism
(serum PTH > 300 pg/mL) with 10 μg of maxacalcitol
intravenously injected thrice a week. They observed, along
with a reduction of PTH levels, a significant decrease
of bone-specific alkaline phosphatase and osteoprotegerin
levels. Osteoprotegerin is a natural glycoprotein which plays
a critical role in osteoclast physiology. Elevated levels of
circulating osteoprotegerinmay account for the development
of bone and mineral metabolic abnormalities in uremia.
3.3. Hospitalization and Mortality (Table 7). There are stud-
ies which demonstrate that VDR activators are able to reduce
hospitalization and mortality. Dobrez et al. [33] observed
in 11 443 hemodialysis patients receiving at least 10 doses
of vitamin D therapy that paricalcitol group had a lower
risk of first all-cause hospitalization (14% less, P < .0001),
fewer hospitalizations per year (0.642 fewer, P < .001), and
fewer hospital days per year (6.84 fewer, P < .001) versus
calcitriol. Vervloet and Twisk [34] analyzed the observational
studies on the association between use of VDR activators
and mortality. They underscored the absence of randomized
controlled trials but considered the available observational
studies “quite robust and consistent”. The hypothesis of
a positive, clinically significant eﬀect of treatment with
VDR activators is supported by the presence of plausible
mechanisms that might explain their observed benefit in
patients on dialysis, beyond their classic role in bone and
mineral metabolism. Specifically, these include inhibition of
renin biosynthesis, modulation of arterial function, positive
eﬀects on left ventricular hypertrophy, attenuation of insulin
resistance, potential positive impact on immune function,
reduced incidence of cancer, and other potential mechanisms
[34]. A seminal study on the possible relationship between
paricalcitol treatment and reduced mortality was published
by Teng et al. [35]. They designed a historical cohort study
to compare the 36-month survival rate among hemodialysis
patients receiving treatment with paricalcitol versus cal-
citriol: mortality rate among patients receiving paricalcitol
was significantly lower versus patients receiving calcitriol
(P < .001). Tentori et al. [36], conduced on 7731 patients
to compare calcitriol, paracaclcitol and doxercalciferol. They
demonstrated that mortality rates were similar in patients
treated with doxercalciferol and paricalcitol, while higher in
patients treated with calcitriol (P < .001). Thus, the survival
benefit in chronic kidney disease patients, independent of the
eﬀects on parathyroid hormone and calcium levels, appears
to be better with the use of vitamin D analogs (paricalcitol
and doxercalciferol), followed by the use of calcitriol, and the
worst survival is associated with no VDR activation therapy.
The mechanisms underlying the cardiovascular and survival
benefit of VDR activators are still under active investigation.
Several diﬀerent potential factors could play a role, as VDR
has been identified in more than 30 diﬀerent tissues in the
human body, including the vasculature [8].
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Table 8: Cardiovascular protection.
Author Year Study Outcome
Bodyak et al. [37] 2007
Study in Dahl salt-sensitive (DSS) rats to
evaluate if paricalcitol is able to attenuate the
development of left ventricular abnormalities
Compared with DSS rats fed a high-salt (HS)
diet (6% NaCl for 6 weeks), DSS rats fed a
high-salt HS receiving paricalcitol showed
lower heart and lung weights, reduced LV
mass, posterior wall thickness and end diastolic
pressures, and increased fractional shortening.
Blood pressures did not significantly diﬀer
between the groups
Xiang et al. [38] 2005
VDR knockout (KO) mice were compared with
wild-type (WT) mice
In VDRKO mice, the cardiac renin mRNA level
was significantly increased, suggesting that the
cardiac hypertrophy in VDRKO mice is a
consequence of activation of both the systemic
and cardiac RAS and that
1,25-dihydroxyvitamin D3 regulates cardiac
functions
Zhou et al. [39] 2008
25(OH)D 1alpha-hydroxylase KO mice were
compared with WT mice to determine whether
the cardiovascular eﬀect of 1,25vitD is
dependent on calcium or phosphorus.
Ablation of the 1alpha-hydroxylase gene in
mice led to hypertension, cardiac hypertrophy,
and systolic dysfunction, and this cardiac
phenotype was rescued with exogenous
1,25vitD administration. 1,25vitD plays a
protective role in the cardiovascular system by
repressing the renin-angiotensin system
independent of extracellular calcium or
phosphorus.
PRIMO study (Paricalcitol
Benefits in Renal Disease
Induced Cardiac Morbidity
Study) [40]
Ongoing
RCT, oral paricalcitol compared to placebo in
220 predialysis patients (GFR 15–45ml/min)
aﬀected by mild-to-moderate LVH and an LV
ejection fraction >50%
Study ongoing
Mizobuchi et al. [41] 2007
Uremic rats (5/6 NX rats) were given calcitriol,
paricalcitol, or doxercalciferol 3/week for 1
month
Calcitriol and doxercalciferol, but not
paricalcitol, increased vascular calcification in
uremic rats. The diﬀerent eﬀects of VDRA on
vascular calcification are independent of an
eﬀect on Ca and P. Doxercalciferol significantly
increased the Ca × P product and the aortic
calcium content. A lower doxercalciferol did
not increase the calcium-phosphate product
but increased the aortic calcium content.
3.4. Cardiovascular Protection (Table 8). One hypothesis
derived from the available observational studies suggests
that systemic activation of VDRs may have direct eﬀects on
the cardiovascular system to decrease mortality in patients
with chronic kidney disease [8]. Vitamin D and its analogs
may play a role in preserving the cardiovascular system
and reducing vascular calcification. In accordance with
this concept, Levin and Li [54] suggested that Vitamin
D deficiency might be an underestimated risk factor for
cardiovascular disease in chronic kidney disease. They also
underscore that evidence from both basic science and clinical
studies supports the possible protective role of vitamin D
beyond its eﬀect on mineral metabolism. Bodyak et al.
[37] studied Dahl salt-sensitive rats fed a high-salt diet
(6% NaCl for 6 weeks) and receiving paricalcitol, showing
lower heart and lung weights, reduced left ventricular mass,
posterior wall thickness and end diastolic pressures, and
increased fractional shortening. Xiang et al. [38] studied
VDR knockout mice and they showed that cardiac renin
mRNA levels were significantly increased, suggesting that
the cardiac hypertrophy in VDR knock-out mice is a con-
sequence of the activation of both the systemic and cardiac
rennin angiotensin system and that 1,25-dihydroxyvitamin
D3 regulates cardiac functions. In another gene knock-out
study by Zhou et al. [39], ablation of the 1alpha-hydroxylase
gene in mice led to hypertension, cardiac hypertrophy, and
systolic dysfunction, and this cardiac phenotype was rescued
with exogenous 1,25-dihydroxyvitamin D administration.
The authors concluded that calcitriol plays a protective
role in the cardiovascular system by repressing the renin-
angiotensin system independent of extracellular calcium or
phosphorus. In humans, the PRIMO study (Paricalcitol Cap-
sules Benefits in Renal Failure Induced Cardiac MOrbidity
Study), a multinational, randomized, double-blinded trial
with oral paricalcitol compared to placebo, is ongoing [40]:
its primary outcome measure is to investigate the eﬀects of
paricalcitol on progression or regression of left ventricular
hypertrophy in Stage 3B/4 chronic kidney disease subjects,
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Table 9: Prevention of atherosclerosis.
Author Year Study Outcome
Husain et al. [42] 2010
A study in atherosclerotic mice to investigate the
protective eﬀect of paricalcitol combined with
angiotensin-converting enzyme inhibitor (enalapril)
on aortic oxidative injury
ApoE-deficient mice developed hypertension which
was prevented by enalapril or enalapril + paricalcitol
treatment (not by paricalcitol alone). Atherosclerotic
plaque in the aorta of ApoE-deficient mice was
prevented by paricalcitol, enalapril, and paricalcitol
+ enalapril treatments
through the evaluation of changes in left ventricular mass
index, in a time frame of 48 weeks.
Mizobuchi et al. [41] studied uremic rats treated with
calcitriol, paricalcitol, or doxercalciferol and found that
calcitriol and doxercalciferol, but not paricalcitol, increase
vascular calcification in uremic rats; in particular the diﬀer-
ent eﬀects of VDR activators on vascular calcification appear
to be independent of serum calcium and phosphate levels.
3.5. Prevention of Atheroscleroisis (Table 9). Husain et al. [42]
conducted a study in atherosclerotic mice to investigate the
protective eﬀect of paricalcitol combined with angiotensin-
converting enzyme inhibition (by enalapril) on aortic oxida-
tive injury. They found that ApoE-deficient mice developed
hypertension, which was prevented by enalapril or by the
combined enalapril and paricalcitol treatment, but not by
paricalcitol alone. On the other hand, atherosclerotic plaque
in the aorta of ApoE-deficient mice was prevented by par-
icalcitol, enalapril, and paricalcitol + enalapril treatments.
Combination therapy aﬀorded greater protection against
aortic inflammatory and oxidative injury in atherosclerosis
than monotherapy. This observation underscores the role of
VCR activators not only as PTH suppressors but also as an
essential treatment in patients with chronic kidney diseases,
which are notoriously more exposed to cardiovascular
diseases and atherosclerosis.
3.6. Renal Protection and Reduction of Proteinuria (Table 10).
Agarwal et al. [43] in three double-blind, randomized,
placebo controlled studies in patients with chronic kidney
disease stage 3 and 4, found a reduction in proteinuria
in 51% of paricalcitol patients versus 25% of placebo
patients (P < .01). The demonstration of a reduction in
proteinuria associated with paricalcitol treatment, indepen-
dent of concomitant use of agents that block the renin
angiotensin system RAA, suggests that paricalcitol is a
potential pharmacologic means of reducing proteinuria in
chronic kidney disease. As a consequence, de Zeeuw et al.
[44] designed a multinational, placebo-controlled, double-
blind trial (VITAL study): patients aﬀected by type 2 diabetes
and albuminuria receiving angiotensin-converting enzyme
inhibitors or angiotensin receptor blockers were randomized
to receive placebo, 1 μg/day paricalcitol, or 2 μg/day parical-
citol. They demonstrated that patients treated with 2 μg of
paricalcitol showed an early and sustained reduction in uri-
nary albumin-to-creatinine ratio versus placebo (P < .05). In
another, smaller double-blind randomized study, Fishbane
et al. [45] randomized 61 patients with estimated glomerular
filtration rate from 15 to 90mL/min/1.73m2 and protein
excretion greater than 400mg/24 h to receive paricalcitol,
1mcg/day, or placebo: changes in protein excretion from
baseline to last evaluation were +2.9% for controls and
−17.6% for the paricalcitol group (P < .05). Zhang et al. [46]
studied streptozotocin- (STZ-) induced diabetic mice and
discovered that treatment with losartan and paricalcitol com-
pletely prevented albuminuria, restored glomerular filtration
barrier structure, and markedly reduced glomerulosclerosis,
preventing renal injury in diabetic nephropathy. Thus,
evidence is available suggesting that inhibition of the rennin
angiotensin system with combination of vitamin D analogs
and rennin angiotensin system inhibitors eﬀectively prevents
renal injury in diabetic nephropathy and it may be associated
with improved renal protection.
3.7. Renal Protection and Inhibition of the Renin-Angiotensin
System (Table 11). Paricalcitol inhibits the rennin-angiot-
ensin system. Freundlich et al. [47], in a study in remnant
kidney model of chronic renal failure (5/6 nephrectomy)
mice, administrated paricalcitol and found that paricalcitol
decreases angiotensinogen, renin, renin receptor, and vascu-
lar endothelial growth factor mRNA levels in the remnant
kidney by 30–50 percent versus untreated animals. Bodyak
et al. [37] also found that paricalcitol significantly reduced
cardiac renin expression in Dahl salt-sensitive rats.
3.8. Renal Protection and Tubular Interstitial Fibrosis
(Table 12). Tan et al. [48], using a mouse model of obstruc-
tive nephropathy, found that paricalcitol attenuates renal
tubulo-interstitial fibrosis. Paricalcitol reduced infiltration of
T cells and macrophages in the obstructed kidney and this
inhibition of inflammatory cell infiltration was accompanied
by a decreased expression of RANTES and TNF-alpha. Their
results suggest that paricalcitol inhibits renal inflammatory
infiltration and RANTES expression by promoting VDR-
mediated sequestration of NF-kappaB signaling. Wang et
al. [49] treated with the VDR agonist doxercalciferol diet-
induced obese mice, presenting proteinuria, renal mesangial
expansion, accumulation of extracellular matrix proteins,
and activation of oxidative stress. Treatment with doxer-
calciferol decreased proteinuria, podocyte injury, mesangial
expansion, and extracellular matrix protein accumulation.
The VDR agonist also decreased macrophage infiltration,
oxidative stress, proinflammatory cytokines, and profibrotic
growth factor. In addition, it prevented the activation
of the renin-angiotensin-aldosterone system including the
angiotensin II type 1 receptor and the mineralocorticoid
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Table 10: Renal protection and reduction of proteinuria.
Author Year Study Outcome
Agarwal et al. [43] 2005
Three RCTs in 220 CKD stage 3 and 4
patients randomized to oral paricalcitol
(N = 107) or placebo (N = 113),
followed for up to 24 weeks
Decreased proteinuria in 29/57 (51%) of
paricalcitol patients versus 15/61 (25%)
placebo patients, P = .004 (odds for
reduction in proteinuria 3.2 times greater
for paricalcitol patients)
de Zeeuw et al. (VITAL study) [44] 2010
Multinational RCT in 281 patients with
type 2 diabetes and albuminuria
receiving angiotensin-converting enzyme
inhibitors or angiotensin receptor
blockers were randomized to receive
24-week treatment with placebo, 1 μg/day
paricalcitol, or 2 μg/day paricalcitol
Patients on 2 μg paricalcitol had an early,
sustained reduction in UACR (urinary
albumin-to-creatinine ratio), ranging
from –18% to −28% (P = .014) versus
placebo
Fishbane et al. [45] 2009
RCT of 61 patients with estimated
glomerular filtration rate from 15 to
90mL/min/1.73m2 and protein excretion
greater than 400 mg/24 h to receive
paricalcitol, 1 mcg/day, or placebo.
Changes in protein excretion from
baseline to last evaluation were +2.9% for
controls and −17.6% for the paricalcitol
group (P < .05).
Zhang et al. [46] 2008
Study in streptozotocin- (STZ-) induced
diabetes model mice
Treatment with losartan and paricalcitol
completely prevented albuminuria,
restored glomerular filtration barrier
structure, and markedly reduced
glomerulosclerosis, eﬀectively preventing
renal injury in diabetic nephropathy
Table 11: Renal protection and inhibition of the rennin-angiotensin system.
Author Year Study Outcome
Freundlich et al. [47] 2008
Study in remnant kidney model of chronic
renal failure (5/6 nephrectomy) mice,
administrating two diﬀerent doses of
paricalcitol thrice weekly for 8 weeks.
Paricalcitol was found to decrease
angiotensinogen, renin, renin receptor, and
vascular endothelial growth factor mRNA
levels in the remnant kidney by 30–50%
compared to untreated animals.
Bodyak et al. [37] 2007
Study in Dahl salt-sensitive (DSS) rats.
Evaluation of the ability of paricalcitol to
attenuate the development of LV abnormalities.
Paricalcitol significantly reduced cardiac
renin expression in DSS rats
receptor. An additional novel finding of this study is that the
VDR activator decreased the accumulation of neutral lipids
(triglycerides and cholesterol) and the expression of enzymes
that mediate fatty acid and cholesterol synthesis.
3.9. Anti-Inflammatory Action (Table 13). In a pilot trial,
Alborzi et al. [50] randomized patients in 3 groups receiv-
ing oral paricalcitol 0, 1, or 2mcg/day. They observed
a reduction of high sensitivity C-reactive protein and of
albuminuria in patients treated with paricalcitol, with a
mechanism independent of its eﬀects on hemodynamics
or PTH suppression, as no diﬀerences were observed in
iothalamate clearance, 24-hour ambulatory blood pressure,
or PTH levels. Eleftheriadis et al. [51] also found that basal
TNF-alpha concentration and basal IL-8 concentration were
reduced by paricalcitol. These studies therefore suggest that
paricalcitol also has immunomodulatory properties, another
reason for administration of paricalcitol in patients with
chronic renal failure. Indeed, patients with chronic kidney
disease have chronic inflammation in the cardiovascular
system and a reduced immunity to infections.
3.10. Endothelial Function (Table 14). VDR activators have
been shown to modulate inflammation, thrombosis, and
vasolidation, which are associated with endothelial dysfunc-
tion [55], and they have a potential for treatment of cardio-
vascular disease, including the improvement of endothelial
dysfunction, which increases cardiovascular disease risk in
chronic kidney disease [56].Wu-Wong et al. [52] suggest that
VDR activation improves endothelial function. They studied
uremic rats (5/6 nephrectomized rat) and demonstrated
that the uremia-impaired aortic relaxation was improved by
paricalcitol (with a short duration of treatment, 2 weeks),
in a dose-dependent manner, independent of serum PTH
levels or blood pressure. PTH suppression alone did not
improve endothelial function since in a separate experiment
cinacalcet suppressed PTH without aﬀecting endothelial-
dependent vasorelaxation. The role of phosphate in uremic
10 International Journal of Nephrology
Table 12: Renal protection and reduction of tubular interstitial fibrosis.
Author Year Study Outcome
Tan et al. [48] 2006
Study of the eﬀects of paricalcitol in a mouse
model of obstructive nephropathy
Paricalcitol reduced infiltration of T cells
and macrophages in the obstructed
kidney and this inhibition of
inflammatory cell infiltration was
accompanied by a decreased expression
of inflammatory cytokines. Paricalcitol
attenuates renal tubulo-interstitial
fibrosis in this animal model of renal
obstructive damage.
Wang et al. [49] 2011
Study in mice with diet-induced obesity, treated
with doxercalciferol.
Doxercalciferol decreased proteinuria,
podocyte injury, mesangial expansion,
extracellular matrix protein
accumulation, macrophage infiltration,
oxidative stress, proinflammatory
cytokines, and profibrotic growth factor.
In addition, it prevented the activation of
the renin-angiotensin-aldosterone
system. VDR activation also decreased
the accumulation of neutral lipids
(triglycerides and cholesterol) and the
expression of enzymes that mediate fatty
acid and cholesterol synthesis.
Table 13: Anti-inflammatory action.
Author Year Study Outcome
Alborzi et al. [50] 2008
A pilot trial in 24 patients randomized to 3
groups to receive 0, 1, or 2 mcg of
paricalcitol orally for 1 month.
At 1 month, the treatment/baseline ratio of high
sensitivity C-reactive protein was 1.5 (95% CI: 1.1 to
2.1; P < .05) with placebo, 0.8 (95% CI: 0.3 to 1.9;
P = .62) with the 1mcg dose, and 0.5 (95% CI: 0.3 to
0.9; P < .05) with a 2 mcg dose of paricalcitol. The
treatment/baseline ratio of 24-hour albumin excretion
rate was 1.35 (95% CI: 1.08 to 1.69; P = .01) with
placebo, 0.52 (95% CI: 0.40 to 0.69; P < .001) with a
1-mcg dose, and 0.54 (95% CI: 0.35 to 0.83; P = .01)
with a 2 mcg dose (P < .001 between group changes).
Eleftheriadis et al. [51] 2010
A study in 10 healthy volunteers; peripheral
blood mononuclear cells (PBMC) were
cultured for 48 hours in presence or not of
lipopolysaccharide (LPS) and in the
presence or not of paricalcitol. TNF-alpha
and IL-8 produced by PBMC were
measured.
Basal TNF-alpha concentration and IL-8
concentrations were reduced by paricalcitol.
Paricalcitol also blunted the TNF-alpha concentration
increase induced by LPS. Paricalcitol reduced to its
basal level the IL-8 concentration increase by LPS. The
in vitro inhibition of TGF-alpha and IL-8 by
paricalcitol confirms the immunomodulatory
properties of this vitamin D analogue.
Table 14: Endothelial function.
Author Year Study Outcome
Wu-Wong et al. [52] 2010
Study in uremic rats (5/6 NX rats),
treated for two weeks with paricalcitol.
Uremia impaired aortic relaxation was improved
by paricalcitol in a dose-dependent manner,
independent of serum PTH levels or blood
pressure. PTH suppression alone did not improve
endothelial function since in a separate
experiment cinacalcet suppressed PTH without
aﬀecting endothelial-dependent vasorelaxation.
Karavalakis et al. [53] 2008
Uremic (5/6 NX) rats treated with
paricalcitol (0.2 mcg/kg, thrice weekly)
for 12 weeks. Aortic histology was studied
Paricalcitol treatment showed both benefits and
harmful eﬀects: vasoconstriction was reduced but
calcification increased. Plasma phosphate was
increased, 2.1- to 2.5-fold higher than normal.
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subjects is important to consider. In the study by Wu-
Wong et al. [52] uremic rats had normal serum phosphate
levels. In a previous study, Karavalakis et al. [53] reported
that, in the 5/6 nephrectomized rats fed a special diet that
induced severe hyperphosphatemia, paricalcitol at 0.2 μg/kg
reduced vasoconstriction but increased vascular calcification.
The improvement of endothelial function by VDR
activators may be one of the mechanisms responsible for the
cardiovascular benefit associated with these agents in chronic
kidney disease.
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